Skip to main content
AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. — Investor Relations & Filings

Listed
Ticker · AIM ISIN · US42366C3016 US Professional, scientific and technical activities
Open in API
Filings indexed 1,095 across all filing types
Latest filing 2024-05-02 Regulatory Filings
Country US United States of America
Listing US AIM

About AIM ImmunoTech Inc.

https://aimimmuno.com/

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various diseases. The company's primary areas of focus include oncology, immune disorders, and viral diseases. Its lead drug candidate is Ampligen® (rintatolimod), a proprietary immuno-modulator with broad-spectrum activity demonstrated in pre-clinical testing. Ampligen® is being evaluated in multiple clinical studies for a range of debilitating and life-threatening conditions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-05-02 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(5) related to a registration statement for resale of common stock by a selling stockholder. It details the terms of a Purchase Agreement for equity financing, including the number of shares, pricing formula, and resale conditions. The document is not a financial report, earnings release, or management discussion, but rather a capital raising and financing disclosure. It is a detailed disclosure about a financing transaction and resale registration, fitting the definition of a Capital/Financing Update (CAP). The document length is substantial and contains detailed terms of the financing arrangement, not merely an announcement or brief summary, so it is not RPA or RNS. Therefore, the appropriate classification is CAP with high confidence.
2024-05-01 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from AIM ImmunoTech Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-1. It is a formal communication related to a securities registration process, specifically requesting the SEC to declare the Form S-1 effective at a certain date and time. The document does not contain financial statements, management discussion, or detailed financial data. It is a regulatory communication related to a capital raising process but is not itself a capital/financing update or a financial report. Given the short length (1559 characters) and the nature of the document as a formal request to the SEC, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2024-04-25 English
Regulatory Filings 2024
Regulatory Filings Classification · 90% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as any specific filing type. According to the fallback rule, when a document does not fit any specific category due to lack of information, it should be classified as a Regulatory Filing (RNS). The document length is 15,000 characters, so it is not a short announcement but the content is unreadable.
2024-04-25 English
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a letter from a law firm to the SEC regarding the submission of a Form S-1 registration statement. It is not the registration statement itself but a correspondence notifying the SEC of the filing. The document is short (1098 characters) and serves as a cover letter rather than a financial or regulatory report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings and correspondence that do not fit other specific categories.
2024-04-19 English
Capital/Financing Update 2024
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the company, the securities being offered, the selling stockholder, and the terms of the offering. This is a capital raising filing related to financing activities, specifically a registration statement for an equity line of credit and resale of shares. It is not an annual report, earnings release, or any other type of report but a capital/financing update. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or notice, so it is not RPA or RNS.
2024-04-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.